scholarly journals Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma

2015 ◽  
pp. 437 ◽  
Author(s):  
Mao-Bin Meng ◽  
Huan-Huan Wang ◽  
Nicholas Zaorsky ◽  
Chao Jiang ◽  
Zhi-Qiang Wu ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Small Cell ◽  
Multimodality Therapy ◽  
Limited Stage

Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma

2013 ◽  
Vol 106 (3) ◽  
pp. 317-322 ◽  
Author(s):  
Mao-Bin Meng ◽  
Nicholas G. Zaorsky ◽  
Chao Jiang ◽  
Li-Jun Tian ◽  
Huan-Huan Wang ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Small Cell ◽  
Limited Stage ◽  
Improved Outcomes

Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: three cases and review of the literature

2010 ◽  
Vol 28 (3) ◽  
pp. 181-187 ◽  
Author(s):  
Yuko Isoyama ◽  
Yoshiyuki Shioyama ◽  
Satoshi Nomoto ◽  
Saiji Ohga ◽  
Takeshi Nonoshita ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Small Cell ◽  
Review Of The Literature ◽  
Limited Stage

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

2021 ◽  
Vol 22 (6) ◽  
pp. e220
Author(s):  
Antonin Levy ◽  
Cécile Le Péchoux ◽  
Corinne Faivre-Finn
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage

scholarly journals Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer

Biology ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 502
Author(s):  
David Dora ◽  
Christopher Rivard ◽  
Hui Yu ◽  
Shivaun Lueke Pickard ◽  
Viktoria Laszlo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cell Counting ◽  
M2 Macrophage ◽  
Strong Positive Correlation ◽  
Small Cell Lung ◽  
Limited Stage ◽  
Macrophage Marker

This study aims to characterize tumor-infiltrating macrophages (TAMs), myeloid-derived suppressor cells (MDSC), and the related molecular milieu regulating anti-tumor immunity in limited-stage neuroendocrine (NE)-high and NE-low small cell lung cancer. Primary tumors and matched lymph node (LN) metastases of 32 resected, early-stage SCLC patients were analyzed by immunohistochemistry (IHC) with antibodies against pan-macrophage marker CD68, M2-macrophage marker CD163, and MDSC marker CD33. Area-adjusted cell counting on TMAs showed that TAMs are the most abundant cell type in the TME, and their number in tumor nests exceeds the number of CD3 + T-cells (64% vs. 38% in NE-low and 71% vs. 18% in NE-high). Furthermore, the ratio of CD163-expressing M2-polarized TAMs in tumor nests was significantly higher in NE-low vs. NE-high tumors (70% vs. 31%). TAM density shows a strong positive correlation with CD45 and CD3 in tumor nests, but not in the stroma. fGSEA analysis on a targeted RNAseq oncological panel of 2560 genes showed that NE-high tumors exhibited increased enrichment in pathways related to cell proliferation, whereas in NE-low tumors, immune response pathways were significantly upregulated. Interestingly, we identified a subset of NE-high tumors representing an immune-oasis phenotype, but with a different gene expression profile compared to NE-low tumors. In contrast, we found that a limited subgroup of NE-low tumors is immune-deserted and express distinct cellular pathways from NE-high tumors. Furthermore, we identified potential molecular targets based on our expression data in NE-low and immune-oasis tumor subsets, including CD70, ANXA1, ITGB6, TP63, IFI27, YBX3 and CXCR2.

scholarly journals MET-04 A case of Brain Metastases with repeated bleeding from Esophageal carcinoma

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii19-ii19
Author(s):  
Masataka Mikai ◽  
Mitsuyoshi Abe ◽  
Yo watanabe ◽  
Chie Nakada ◽  
Yutaka Huchinoue ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Brain Metastases ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Cerebral Hemorrhage ◽  
Small Cell ◽  
The Body ◽  
Metastatic Brain Tumor ◽  
Carcinoma Of The Esophagus

Abstract Brain metastases from esophageal cancer is rare and the incidence has been reported at approximately 5%. We report a case of brain metastases with repeated bleeding from Esophageal carcinoma. The case is a 76-year-old man. Three years ago he was diagnosed with small cell carcinoma of the esophagus by endoscopic biopsy. Metastasis was found only in the cervical lymph node, but the condition was stable by chemoradiotherapy and no metastases were found throughout the body before 1 month. He was admitted to the hospital because of a sudden convulsion, and CT scan revealed cerebral hemorrhage in the right frontal lobe. We performed conservative treatment, but rebleeding was observed from the same site repeatedly after 1 month and 2 months. Due to the influence of bleeding, it was difficult to distinguish cerebral hemorrhage from brain tumor by contrast MRI. After surgery, the cause of bleeding was diagnosed as metastatic brain tumor of esophageal small cell carcinoma. Postoperative radiation therapy was performed in another hospital, but rebleeding was observed 3 months after the operation. A reoperation was performed at another hospital, and a recurrence of metastatic brain tumor was diagnosed. In the case of highly malignant metastatic brain tumors, it was considered necessary to frequently follow the images.

scholarly journals Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes

2021 ◽  
Vol 28 (1) ◽  
pp. 317-331
Author(s):  
Sarah Sharman Moser ◽  
Jair Bar ◽  
Inna Kan ◽  
Keren Ofek ◽  
Raanan Cohen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Real World ◽  
Treatment Patterns ◽  
Small Cell ◽  
Multivariable Model ◽  
Small Cell Lung ◽  
Limited Stage ◽  
Extensive Stage

In this observational study, we assessed treatment patterns and prognostic factors in patients with small cell lung cancer (SCLC) in a large state-mandated healthcare organization in Israel. Methods: All incident cases with histologically confirmed SCLC who initiated systemic anti-cancer treatment between 2011 and 2017 were identified. Treatment patterns and overall survival (OS) were evaluated for each line of therapy. Results: A total of 235 patients were identified (61% male, median age 64 years, 95% ever smokers, 64% had extensive stage). The first-line treatment was platinum–etoposide regimen for 98.7% of the cohort. The second and third-line regimen were given to 43% and 12% of patients, respectively. Mean OS for extensive and limited stage patients was 9.1 and 23.5 months respectively. In a multivariable model, increased risk for mortality was observed among patients with an ECOG performance status (PS) of 2 compared to a PS of 0–1 for the extensive stage patients (Hazard ratio (HR) = 1.63, 95% confidence ratios (CI): 1.00–2.65); and for males compared to females for the limited stage patients (HR = 2.17; 95% CI: 1.12–4.20). Regarding all 2nd line patients in a multivariable model incorporating relevant confounding factors, demonstrated a significantly better outcome with platinum–based regimens compared to topotecan. Median survival after initiation of 2nd line in platinum-sensitive patients was longer (p = 0.056) for those re-challenged with platinum–based regimen (n = 7): 6.8mo (6.1-not reported (NR)), compared with those switched to a different treatment (n = 27): 4.5 mo (2.6–6.6) for extensive stage patients, and a non-significant difference was also observed for limited stage patients. Conclusion: To our knowledge, this is one of the largest real-world studies of SCLC patients. OS for SCLC patients was similar to that reported in clinical trials. PS for extensive stage patients and sex for limited stage patients were significant correlates of prognosis. Re-challenge of the platinum–based doublet was associated with longer OS compared to switching treatment in extensive stage patients.

Sign in / Sign up

Export Citation Format

Share Document